BrightInsight Raises Significant Capital to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization
Today we announced the exciting news that BrightInsight raised significant capital from top healthcare venture capital firm, New Leaf Venture Partners, and leading technology venture capital firm, Eclipse Ventures. It has been an incredibly busy few months leading up to today’s announcement and I am thrilled to share the details with you.
This transformational financing will enable us to continue to enhance the functionality and robustness of the BrightInsight Platform as well as accelerate our global expansion efforts. We will also invest in integrating our platform into the broader healthcare ecosystem, including Electronic Medical Records (EMRs), payers and disease management programs.
BrightInsight’s funding validates the open ecosystem approach that we have taken.
As venture funding continues to pour into the digital health space (and set investment records year over year), it’s imperative that we focus as an industry on ecosystem integration. We don’t want to look back 5 or 10 years from now having invested billions of dollars and be left with another siloed set of solutions, à la Electronic Medical Records.
I’ve talked a lot in the past about how BrightInsight differs, and that we are taking an open ecosystem approach to enable our biopharma and medtech customers to integrate data across therapies, brands and into the larger healthcare ecosystem. The fact that leading VCs in both the healthcare and technology industries who look at thousands of companies are investing in us validates our open approach and recognizes that the future of healthcare is going to require ecosystem integration.
This capital marks yet another important milestone for BrightInsight.
Since launching the BrightInsight Platform in 2018 we have become the leading global regulated digital health platform for the world’s top biopharma and medtech companies. We were selected as Novo Nordisk’s global digital health partner to develop innovative solutions for diabetes patients. Additionally, we announced the launch of a dosing calculator to treat patients with Hemophilia A, which was sponsored by F. Hoffmann-La Roche.
In the past year alone, we have also seen validation from leading technology companies and third-party media outlets. We were selected as the “Best IoT Healthcare Platform” in the 2019 MedTech Breakthrough Awards and included in CIOReview Magazine’s “20 Most Promising Biotech Solution Providers 2019″. We were also awarded “2018 Google Cloud Partner of the Year for Healthcare and Life Sciences” by the world’s leading tech titan.
To say I’m proud of our team would be an understatement.
More details on the funding can be found in our press release.